Light AI pilots Strep A diagnostic in NZ as FDA pivotal trial launches, but pre-revenue status and going concern risk persist.
LIGHT AI ANNOUNCES COMPANY-FUNDED FIELD STUDY IN NEW ZEALAND FOR QUICKSCAN(TM) STREP A PLATFORM
Healthcare
Page 7- Jun 15, 2026 · 16:36 · BETR · Routine −01
Pre-revenue psychedelic-adjacent biotech secures critical $2M lifeline amid severe liquidity crunch.
Betterlife arranges $2-million debenture financing
- Jun 15, 2026 · 07:30 · APS · Routine +02
Clinical data validates tuspetinib's AML potential, but acquisition hinges on delayed Korean regulatory approval.
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
- Jun 15, 2026 · 07:00 · XRTX · Routine +03
Micro-Cap Biotech Secures FDA Pathway Clarity and Capital, but Execution Risk Remains High
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
- Jun 15, 2026 · 03:45 · BNXT · Routine +04
BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
- Jun 12, 2026 · 18:15 · HBP · Routine +05
Helix Biopharma Secures $3.67M Lifeline via Convertible Debentures, Cuts Losses as It Winds Down Pancreatic Trial
Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026
- Jun 12, 2026 · 17:15 · BNXT · Routine +06
Cash-Strapped Formulation Platform Raises $2M Lifeline Amid Dilutive Discount and Ongoing Clinical Execution
BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
- Jun 12, 2026 · 17:00 · VVTM · Routine −07
Bi-weekly regulatory update on delayed filings and ongoing MCTO restricts insider trading while commercial expansion continues.
VVT Med Provides Update on Management Cease Trade Order
- Jun 12, 2026 · 07:02 · WELL · Routine +08
WELL Health Provides a Corporate Update on Circle Medical
WELL Health Provides a Corporate Update on Circle Medical
- Jun 11, 2026 · 17:01 · BPC · Routine −09
Pre-revenue peptide developer secures at-market capital to fund U.S. commercial rollout amid regulatory tailwinds.
The Precision Peptide Company Inc. Announces up to $2 Million LIFE Offering of Common Shares
- Jun 11, 2026 · 16:31 · CHER · Neutral10
Small-cap mobility device maker scales commercialization but relies on recurring capital raises to fund cash burn.
Cheelcare Announces a Non-Brokered Private Placement to Raise up to $1.5 Million
- Jun 11, 2026 · 16:30 · ZYUS · Routine +11
Streamlining operations and shedding non-core assets to preserve cash ahead of critical Phase 2a data readout amid regulatory filing delays.
ZYUS Life Sciences Announces Strategic Realignment to Prioritize Drug Development
- Jun 11, 2026 · 11:18 · APTX · Routine +12
Canadian pharma giant completes $1.3B IPO, debuts on TSX with a 12.5% pop.
Apotex Health Corp. (APTX) Opens the Market
- Jun 11, 2026 · 08:30 · TSXV: · Routine +13
VVT Med Advances Global Commercial Rollout of ScleroSafe with Dominican Republic Entry and Tranche 2 Financing
VVT Med Expands into the Dominican Republic, Appointing Antilles Medical as Exclusive Distributor
- Jun 11, 2026 · 08:30 · VVTM · Routine +14
Early-stage venous disease device maker scales global distribution while navigating regulatory delays and dilutive capital raises.
VVT Med Expands into the Dominican Republic, Appointing Antilles Medical as Exclusive Distributor